Facebook
X
LinkedIn
Forward
Advanced Pharmacology at the Edge of Care: Precision, Pragmatism, and Palliative Reality
This workshop offers participants a self-guided learning material alongside a 6-hour live virtual an in-depth exploration of CAMP (Complementary and Alternative Pharmaceuticals), end of life pharmacological treatment, patient substance abuse, and a perspective on the dynamic use of buprenorphine in hospice and palliative care. With over 5 hours of accredited learning, this course is specifically designed for advanced clinicians and those professionals with prescribing privileges with the goal of providing an enhanced understanding of drug therapy principles and their clinical applications.
Session Outline
Sessions listed in Central Time
| Time | Session | Faculty |
|---|---|---|
| 10:05 am - 11:25 am | Not Harmless, Not Hopeless: Complementary Pharmaceuticals in Palliative Care | Dr. Mary Lynn McPherson |
| 11:40 am - 1:00 pm | Psychopharmacology at the End of Life: Choosing the Right Drug for the Right Moment | Dr. Jeremy Hirst |
| 1:00 pm - 2:20 pm | Care at the Crossroads: An Approach to Patients with Advanced Illness who Use Substances | Dr. Julie Childers |
| 2:35 pm - 3:55 pm | From OUD to Analgesia: Buprenorphine’s Expanding Role in Serious Illness | Dr. Marcin Chwistek Dr. Mellar P. Davis |
Target Audience
This course is specifically designed for advanced clinicians and professionals with prescribing privileges, but we encourage all interdisciplinary HPM care professionals to attend, including:
- Physicians
- Advanced Practice Providers
- Nurses
- Pharmacists
- Other clinicians responsible for symptom management in seriously ill patients.
Learning Outcomes
By the end of this workshop, participants will be able to:
- Apply complex pharmacologic principles to make informed prescribing decisions for patients with serious illness, including drug selection, dosing and delivery.
- Evaluate and adjust maintenance medication regimens at end of life based on prognosis, symptom burden, and patient goals to optimize safety and effectiveness.
- Identify strategies to balance pain control with management of addiction in patients with advanced illness.
- Develop a practical approach to initiating, rotating to, and managing buprenorphine for analgesia in palliative care populations, including patients with multimorbidity, renal impairment, prior to full-agonist exposure, and concurrent opioid use disorder.
Disclosures
AAHPM endorses the Accreditation Council for Continuing Medical Education (ACCME) Standards for disclosure and commercial support and endeavors to ensure balance, independence, objectivity, and scientific rigor for all accredited products or programs. All who are in a position to control or influence the content of an educational activity must disclose any relevant financial relationships with ineligible companies.*Disclosure documents were reviewed for potential conflicts of interest and, if identified, were resolved prior to confirmation of participation. Only those who had no conflict of interest or who agreed to an identified resolution process prior to their participation were involved in this activity.
All editors, faculty and staff have disclosed no relevant financial relationships.
*An ineligible company is defined as any entity producing, marketing, reselling, or distributing healthcare goods or services consumed by, or used on, patients.
Faculty
Mary Lynn McPherson, PharmD PhD FAAHPM
Jeremy Hirst, MD
Julie Childers, MD
Marcin Chwistek, MD FAAHPM
Mellar P. Davis, MD FCCP FAAHPM
Staff
Katie Siesel, BS
Emily Geary, BA
Krys Hansen, MS
To Update: This section must include language, even if it's non-accredited. IF accredited, please copy language from another accredited Learn activity. Make sure to edit number of credit and credit types as needed (amount and type of credits can be copied from PARS activity). IF non-accredited, please copy language from another non-accredited Learn activity.
Available Credit
- 5.25 ABIM MOC
- 5.25 CME (physician only)
- 5.25 Participation